Synthetic method of natural product Racemosin B
Using indole, a cheap and readily available starting material, a three-step mild reaction method was adopted to synthesize Racemosin B, which solved the problems of expensive starting materials and harsh reactions in existing technologies. This method is efficient and environmentally friendly and promotes drug development.
Patent Information
- Application Number
- CN202511077444.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-01
- Publication Date
- 2025-11-11
AI Technical Summary
Existing methods for synthesizing Racemosin B suffer from problems such as high starting material costs, insufficient commercial supply, or harsh reaction conditions, making it difficult to meet the needs of drug development.
Racemosin B is synthesized from indole, a cheap and readily available starting material, through a three-step reaction, including iodination, coupling, and cyclization reactions carried out under mild conditions. This avoids the use of strong acids, strong bases, and carcinogenic solvents, and uses inexpensive catalysts and readily available raw materials, simplifying the operation steps.
This method enables the efficient synthesis of Racemosin B, reduces production costs, simplifies the operation process, conforms to green chemistry principles, and reduces environmental burden.
Smart Images

Figure CN120923505A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of organic compound synthesis technology, and more particularly to a method for synthesizing the natural product Racemosin B. Background Technology
[0002] Racemosin B is a bisindole alkaloid isolated from the green algae *Caulerpa racemosa*, possessing both neuroprotective and anticancer activities (Fitoterapia 2013, 91, 15–20). Its derivatives have shown significant activity against triple-negative breast cancer (such as MDA-MB-231 cells) (IC50). 50 =1.06 μM), the mechanism of action involves inducing G2 / M phase arrest, promoting apoptosis, and inhibiting autophagy, specifically manifested as inhibited LC3-II degradation and p62 protein accumulation (Bioorg. Med. Chem. 2018, 26, 6096–6104; Biochem. Pharmacol. 2022, 201, 115060). However, natural extraction methods are limited by the scarcity of raw materials and low extraction efficiency, making it difficult to meet the needs of in-depth research and drug development. Therefore, developing efficient and scalable chemical synthesis methods is of great significance for promoting the structural optimization, structure-activity relationship study, and anti-tumor drug development of Racemosin B.
[0003] The existing methods for synthesizing Racemosin B mainly include the following: (1) Tetrahedron Lett. 2015, 56, 434 reported a method for synthesizing Racemosin B by constructing the core skeleton from tryptophan via a transamination / aromatic cyclization tandem reaction. This method has the problems of long steps (5 steps) and low overall yield.
[0004]
[0005] (2) Beilstein J. Org. Chem. 2016, 12, 2490 reported a method for synthesizing Racemosin B from 2,4-dibromobenzoic acid via palladium-catalyzed bis-Buchwald-Hartwig coupling followed by oxidative cyclization. The main problem with this method is the high cost of the starting materials (approximately ¥1300 / 100g).
[0006] (3) Org. Lett. 2018, 20, 5348 reported a [1+2+3] cyclization strategy involving o-alkenylaryl isonitriles and unsaturated ketones to synthesize Racemosin B. The main problems with this strategy are that the regioselectivity is uncontrollable and the o-alkenylaryl isonitriles are not commercially available, requiring multiple pre-preparation steps, which increases the complexity of the operation.
[0007]
[0008] (4) Org. Lett. 2023, 25, 8284 reported a palladium-catalyzed π-extended reaction strategy for the synthesis of Racemosin B from indole and acrolein. The main problems with this strategy are that it requires the use of expensive palladium catalyst [Pd(4-PhTPy)(TFA)] (TFA) and an saturation of Cu(OAc)2 oxidant, and acrolein is prone to polymerization side reactions; in addition, benzene, a strong carcinogen, is required as a solvent in the deprotection process.
[0009]
[0010] (5) Although the photochemical synthesis of Racemosin B reported by Synlett 2024, 35, 1929 avoids the use of metal catalysts, its key drawback is that the starting material 1H,1'H-[2,3'-biindole]-3-carboxaldehyde needs to undergo multiple transformations such as Vilsmeier-Haack formylation, and the starting material is not commercially available.
[0011]
[0012] Currently, these methods generally suffer from problems such as high starting material costs, insufficient commercial supply, or harsh reaction conditions (e.g., reliance on expensive catalysts or highly toxic solvents). Therefore, developing new modular, highly selective, and green synthesis strategies is of great significance for advancing the drug development of Racemosin B. Summary of the Invention
[0013] To address the problems existing in the prior art, the present invention aims to provide a method for synthesizing the natural product Racemosin B.
[0014] To achieve the above objectives, the technical solution provided by the present invention is as follows: A method for synthesizing the natural product Racemosin B, characterized by comprising the following steps: S1: Compound 1 and potassium hydroxide were dissolved in N,N-dimethylformamide at room temperature. Iodine solution was added dropwise to the above reaction solution at room temperature. After stirring at room temperature for 30 minutes, potassium hydroxide and 4-toluenesulfonyl chloride were added to the above reaction solution sequentially without separation. After stirring at room temperature for 3 hours, compound 2 was obtained after post-treatment. S2: Compound 2 was dissolved in 1,4-dioxane, and cesium carbonate, tris(2-furan)phosphine, palladium chloride, norbornene, p-toluenesulfonic anhydride and methyl acrylate were added sequentially at room temperature. The mixture was stirred at 90°C for 19 h under inert gas protection, and compound 3 was obtained after post-treatment. S3: Compound 3 was dissolved in acetonitrile, elemental iodine was added at room temperature, and the mixture was irradiated with a 365nm light and stirred at room temperature for 12 hours to achieve a one-pot reaction of cyclization and deprotection. After post-treatment, the natural product Racemosin B was obtained. The chemical reaction formula for the synthesis of the natural product Racemosin B is as follows: .
[0015] Furthermore, the iodine solution mentioned in step S1 is elemental iodine dissolved in N,N-dimethylformamide, and the ratio of elemental iodine to N,N-dimethylformamide is 1g elemental iodine / 8mL N,N-dimethylformamide.
[0016] Furthermore, the post-processing method described in step S1 involves adding distilled water for water precipitation, filtering to collect the solid, washing the solid with distilled water, and washing the solid with petroleum ether to obtain compound 2.
[0017] Furthermore, the molar ratio of compound 2, cesium carbonate, tris(2-furan)phosphine, palladium chloride, norbornene, p-toluenesulfonic anhydride, and ethyl acrylate in step S2 is 1:3:0.2:0.1:1:1:2.
[0018] Furthermore, the molar ratio of compound 3 and elemental iodine in step S3 is 1:(0.01-0.05).
[0019] The method of this invention can efficiently synthesize the natural product Racemosin B. Compared with the prior art, this invention has the following advantages: 1. The raw materials of this invention are commercially available: using indole, which is cheap and readily available, as the only starting material reduces the operational complexity and production cost of synthesizing Racemosin B. 2. The reaction conditions of this invention are mild: all steps are completed under mild conditions (room temperature - 90°C), without involving ultra-low or ultra-high temperatures; 3. The method involved in this invention has a short procedure: the natural product Racemosin B can be obtained in three steps, which has the advantage of step economy; 4. This invention reduces the use of harmful reagents: It avoids the use of harmful reagents such as strong acids, strong bases, and carcinogenic solvents, which is in line with the principles of green chemistry and reduces the environmental burden. Attached Figure Description
[0020] Figure 1 For compound 2 1 H-NMR (400MHz, CDCl3) plot; Figure 2 For compound 3 1 1H NMR (400 MHz, CDCl3) image; Figure 3 For compound 3 13 C NMR (101 MHz, CDCl3) plot; Figure 4 For the compound Racemosin B 1 H-NMR (100MHz, DMSO-d6) image.
[0021] Figure 5 For the compound Racemosin B 13 C-NMR (100MHz, DMSO-d6) plot. Detailed Implementation
[0022] To better explain the present invention, the following detailed description is provided in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are for illustrative purposes only and are not intended to limit the scope of the invention.
[0023] (1) Synthesis of compound 2
[0024] In a dry 100 mL single-necked round-bottom flask equipped with a stir bar, indole (2 mmol, 0.23 g, 1.0 equiv.), potassium hydroxide (5 mmol, 0.28 g, 2.5 equiv.), and N,N-dimethylformamide solvent (6 mL) were added sequentially. The mixture was stirred until the indole substrate was completely dissolved. Then, freshly prepared iodine solution (2.0 g / mL elemental iodine) was added. mmol, 0.51 g, 1.01 equiv (dissolved in 4 mL of N,N-dimethylformamide) was slowly added dropwise to the above reaction solution. After stirring at 25 °C for about 30 minutes, and confirming by thin-layer chromatography that the starting material was completely consumed, potassium hydroxide (5 mmol, 0.28 g, 2.5 equiv.) and 4-toluenesulfonyl chloride (4.2 mmol, 0.8 g, 2.1 equiv.) were added directly to the above reaction solution without separation. The mixture was stirred in an oil bath at the same temperature for 3 hours. After confirming by thin-layer chromatography that the first step product was completely reacted, distilled water (25 mL) was added and stirred for about 10 minutes, after which a large amount of solid precipitated. The solid was collected by filtration and washed successively with distilled water (25 mL x 2) and petroleum ether (25 mL x 2). After drying under reduced pressure at 40 °C, compound 2 (0.63 g, white solid, yield 80%) was obtained. Figure 1 As shown, 1 H NMR (400MHz, CDCl3) δ 8.01 – 7.95 (m, 1H), 7.80 (d, J = 8.3 Hz, 2H), 7.72 (s, 1H), 7.43 – 7.23 (m, 5H), 2.37 (s, 3H). The NMR data are consistent with those reported in Eur. J. Org. Chem. 2013 4564-4569.
[0025] (2) Synthesis of compound 3
[0026] Compound 2 (0.2 mmol, 79.4 mg, 1.0 equiv.), palladium chloride (0.02 mmol, 3.5 mg, 10 mol%), cesium carbonate (0.6 mmol, 195.5 mg, 3 equiv.), tris(2-furan)phosphine (0.04 mmol, 9.3 mg, 20 mol%), p-toluenesulfonic anhydride (0.2 mmol, 65.3 mg, 1.0 equiv.), and norbornene (0.2 mmol, 18.8 mg, 1.0 equiv.) were added sequentially to a reaction tube equipped with a stir bar. Methyl acrylate (0.4 mmol, 42 μL, 2.0 equiv.) was added to the reaction tube using a microsyringe, and the tube was sealed with a rubber stopper. 2 mL of 1,4-dioxane was added to the reaction tube, and the tube was placed under a double-row tube for venting to remove air. Nitrogen gas was added, and the mixture was stirred in an oil bath at 90 °C for 19 h. The reaction mixture was cooled to room temperature, and the reaction was determined to be complete by thin-layer chromatography. Add an appropriate amount of ethyl acetate to the reaction solution, filter, collect the filtrate, concentrate under reduced pressure, mix with silica gel, and purify by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1-10:1, V / V). Concentrate under reduced pressure to remove the solvent, and dry to obtain compound 3 (pale yellow solid, 52.4 mg, yield 84%). Figure 2 As shown, 1 H NMR (400 MHz, CDCl3) δ 8.46 (dt, J = 8.3, 0.9 Hz, 1H), 8.02 – 7.92 (m, 3H), 7.90 – 7.83 (m, 1H), 7.68 (s, 1H),7.49 (ddd, J = 8.5, 7.3, 1.3 Hz, 1H), 7.44 – 7.28 (m, 5H), 7.10 (td, J = 7.5,1.0 Hz, 1H), 7.06 – 6.98 (m, 3H), 6.83 (d, J = 8.1 Hz, 2H), 6.46 (d, J = 16.3Hz, 1H), 3.70 (s, 3H), 2.38 (s, 3H), 2.21 (s, 3H). For example... Figure 3 As shown, 13C NMR (101 MHz, CDCl3) δ 167.42, 145.61, 145.25, 138.32, 136.00, 135.24, 134.99, 134.18,133.91, 131.13, 130.36, 129.51, 129.05, 127.62, 127.39, 126.86, 126.03,125.17, 124.84, 123.77, 120.93, 120.56, 119.95, 119.16, 116.36, 113.50,111.48, 51.66, 21.79, 21.58. (3) Synthesis of Racemosin B
[0027] In a round-bottom flask equipped with a stirrer, compound 3 (0.08 mmol, 50.0 mg, 1.0 equiv.) and elemental iodine (0.0008 mmol, 2.0 mg, 1 mol%) were dissolved in anhydrous acetonitrile (5 mL). The reaction solution was irradiated under a 365 nm UV lamp and stirred at room temperature under a nitrogen atmosphere for 12 hours. TLC analysis confirmed complete consumption of the starting materials. The reaction solution was concentrated by rotary evaporation, and the crude product was purified by column chromatography (petroleum ether: ethyl acetate = 5:1, V / V). The solvent was removed by concentration under reduced pressure, and the product was dried to obtain compound Racemosin B (white solid, 15.3 mg, yield 61%). Figure 4 As shown, 1 H NMR (400 MHz, DMSO-d6) δ 12.06 (s, 1H), 11.55 (s, 1H), 8.84 (s, 1H), 8.68 (dd, J = 7.8, 1.1Hz, 1H), 8.23 (d, J = 7.7 Hz, 1H), 7.84 (dt, J = 8.2, 0.9 Hz, 1H), 7.67 (dt, J = 8.1, 0.9 Hz, 1H), 7.44 (dddd, J = 16.3, 8.2, 7.1, 1.2 Hz, 2H), 7.35 (ddd, J = 8.0, 7.1, 1.1 Hz, 1H), 7.26 (ddd, J = 8.0, 7.2, 1.0 Hz, 1H), 4.03 (s, 3H). (e.g.) Figure 5 As shown, 13 C NMR (101 MHz, DMSO-d6) δ 166.96, 140.17, 138.94, 138.29,137.18, 124.70, 124.66, 123.47, 121.06, 120.93, 120.53, 119.96, 119.40,115.00, 112.01, 111.37, 106.65, 104.51, 51.59. The specific embodiments described herein are merely illustrative of the spirit of the invention. Those skilled in the art to which this invention pertains may make various modifications or additions to the described specific embodiments or use similar methods to substitute them, without departing from the spirit of the invention or exceeding the scope defined by the appended claims.
Claims
1. A method for synthesizing the natural product Racemosin B, characterized in that, Includes the following steps: S1: Compound 1 and potassium hydroxide were dissolved in N,N-dimethylformamide at room temperature. Iodine solution was added dropwise to the above reaction solution at room temperature. After stirring at room temperature for 30 minutes, potassium hydroxide and 4-toluenesulfonyl chloride were added to the above reaction solution sequentially without separation. After stirring at room temperature for 3 hours, compound 2 was obtained after post-treatment. S2: Compound 2 was dissolved in 1,4-dioxane, and cesium carbonate, tris(2-furan)phosphine, palladium chloride, norbornene, p-toluenesulfonic anhydride and methyl acrylate were added sequentially at room temperature. The mixture was stirred at 90°C for 19 h under inert gas protection, and compound 3 was obtained after post-treatment. S3: Compound 3 was dissolved in acetonitrile, elemental iodine was added at room temperature, and the mixture was irradiated with a 365nm light and stirred at room temperature for 12 hours to achieve a one-pot reaction of cyclization and deprotection. After post-treatment, the natural product Racemosin B was obtained. The chemical reaction formula for the synthesis of the natural product Racemosin B is as follows: 。 2. The method for synthesizing the natural product Racemosin B according to claim 1, characterized in that: The iodine solution mentioned in step S1 is elemental iodine dissolved in N,N-dimethylformamide, with the ratio of elemental iodine to N,N-dimethylformamide being 1g elemental iodine / 8mL N,N-dimethylformamide.
3. The method for synthesizing the natural product Racemosin B according to claim 1, characterized in that: The post-processing method described in step S1 is to add distilled water for water precipitation, filter and collect the solid, wash the solid with distilled water, and wash the solid with petroleum ether to obtain compound 2.
4. The method for synthesizing the natural product Racemosin B according to claim 1, characterized in that: The molar ratio of compound 2, cesium carbonate, tris(2-furan)phosphine, palladium chloride, norbornene, p-toluenesulfonic anhydride, and ethyl acrylate in step S2 is 1:3:0.2:0.1:1:1:
2.
5. The method for synthesizing the natural product Racemosin B according to claim 1, characterized in that: The molar ratio of compound 3 and elemental iodine in step S3 is 1:(0.01-0.05).
